EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insights into the expanding intestinal phenotypic spectrum of SOCS1 haploinsufficiency and therapeutic options

Marco M Rodari, Dominique Cazals-Hatem, Mathieu Uzzan, Nicolas Martin Silva, Anis Khiat, Minh Chau Ta, Ludovic Lhermitte, Aurore Touzart, Sylvain Hanein, Cléa Rouillon, Francisca Joly, Adrienne Elmorjani und 4 weitere

Journal of Clinical Immunology · 2023

DOI: 10.1007/s10875-023-01495-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2023. Verfasst von Marco M Rodari und 15 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Cité, Institut Imagine, Laboratory of Intestinal Immunity, INSERM U1163, Paris, France. Hauptthemen laut MEDLINE: Haploinsufficiency, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation pour la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Hyper activation of the JAK-STAT signaling underlies the pathophysiology of many human immune–mediated diseases. Herein, the study of 2 adult patients with SOCS1 haploinsufficiency illustrates the severe and pleomorphic consequences of its impaired regulation in the intestinal tract.

Methods

Two unrelated adult patients presented with gastrointestinal manifestations, one with Crohn’s disease-like ileo-colic inflammation refractory to anti-TNF and the other with lymphocytic leiomyositis causing severe chronic intestinal pseudo-occlusion. Next-generation sequencing was used to identify the underlying monogenic defect. One patient received anti-IL-12/IL-23 treatment while the other received the JAK1 inhibitor, ruxolitinib. Peripheral blood, intestinal tissues, and serum samples were analyzed before-and-after JAK1 inhibitor therapy using mass cytometry, histology, transcriptomic, and Olink assay.

Results

Novel germline loss-of-function variants in SOCS1 were identified in both patients. The patient with Crohn-like disease achieved clinical remission with anti-IL-12/IL-23 treatment. In the second patient with lymphocytic leiomyositis, ruxolitinib induced rapid resolution of the obstructive symptoms, significant decrease of the CD8+ T lymphocyte muscular infiltrate, and normalization of serum and intestinal cytokines. Decreased frequencies of circulating Treg cells, MAIT cells, and NK cells, with altered CD56 bright :CD16 lo :CD16 hi NK subtype ratios were not modified by ruxolitinib.

Conclusion

SOCS1 haploinsufficiency can result in a broad spectrum of intestinal manifestations and need to be considered as differential diagnosis in cases of severe treatment-refractory enteropathies, including the rare condition of lymphocytic leiomyositis. This provides the rationale for genetic screening and considering JAK inhibitors in such cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HaploinsufficiencyTumor Necrosis Factor InhibitorsAdultHumansSuppressor of Cytokine Signaling ProteinsInterleukin-12Interleukin-23Suppressor of Cytokine Signaling 1 ProteinNitrilesPyrazolesPyrimidines

Stichwörter der Autor:innen

Autoimmune enteropathyJAK inhibitionJAK-STATSOCS1 haploinsufficiency

Substanzen

Tumor Necrosis Factor InhibitorsSuppressor of Cytokine Signaling ProteinsInterleukin-12Interleukin-23Suppressor of Cytokine Signaling 1 ProteinruxolitinibNitrilesPyrazolesPyrimidinesSOCS1 protein, human

Autor:innen und Institutionen

  • Université Paris-Cité, Institut Imagine, Laboratory of Intestinal Immunity, INSERM U1163, Paris, France.
  • Department of Pathology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Clichy, France.
  • Department of Gastroenterology, IBD unit, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Clichy, France.
  • Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Gastroenterology department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, F-94…
  • Department of Internal Medicine, Caen University Hospital, Caen, France.
  • Université Paris Cité, Institut Necker Enfants-Malades INEM, Institut National de La Santé Et de La Recherche Médicale (Inserm), U1151, Paris, France.

ORCID-Profile: Marianna Parlato

Förderung

  • Fondation pour la Recherche Médicale

Zitieren

APA

Rodari, M. M., Cazals-Hatem, D., Uzzan, M., Martin Silva, N., Khiat, A., Ta, M. C., Lhermitte, L., Touzart, A., Hanein, S., Rouillon, C., Joly, F., Elmorjani, A., Steffann, J., Cerf-Bensussan, N., Parlato, M., & Charbit-Henrion, F. (2023). Insights into the expanding intestinal phenotypic spectrum of SOCS1 haploinsufficiency and therapeutic options. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-023-01495-7

Vancouver

Rodari MM, Cazals-Hatem D, Uzzan M, Martin Silva N, Khiat A, Ta MC, et al. Insights into the expanding intestinal phenotypic spectrum of SOCS1 haploinsufficiency and therapeutic options. Journal of Clinical Immunology. 2023. doi:10.1007/s10875-023-01495-7

BibTeX
@article{Rodari2023,
  author = {Rodari, Marco M and Cazals-Hatem, Dominique and Uzzan, Mathieu and Martin Silva, Nicolas and Khiat, Anis and Ta, Minh Chau and Lhermitte, Ludovic and Touzart, Aurore and Hanein, Sylvain and Rouillon, Cléa and Joly, Francisca and Elmorjani, Adrienne and Steffann, Julie and Cerf-Bensussan, Nadine and Parlato, Marianna and Charbit-Henrion, Fabienne},
  title = {Insights into the expanding intestinal phenotypic spectrum of SOCS1 haploinsufficiency and therapeutic options},
  journal = {Journal of Clinical Immunology},
  year = {2023},
  doi = {10.1007/s10875-023-01495-7}
}
Kostenlos starten →